Introduction
e prevalence of allergic diseases including atopic dermatitis (AD) has increased over the last decades. In Europe and in the USA, the prevalence of AD is estimated to be 10-20% in infants and 2-3% in adults (Leung et al., 2007) . According to the hygiene hypothesis the increasing number of patients with allergy is ascribed to improved sanitation and reduced microbial exposure. Children from families with worse material status and/or from families with many children and those who contact domestic animals develop allergic diseases less o en (Strachan 1989; Remes et al., 2003; De Meer et al., 2005) . Microorganisms colonizing the human gastrointestinal tract and in particular the bowels play a key role in the formation of protective barrier and stimulation of the immune system. e predisposition to allergy, in ammatory bowel disease (IBD), and autoimmune disorders can be an e ect of wrong primary succession of intestinal microbiota (Kelly et al., 2007) . e gastrointestinal tract of healthy newborns delivered in natural conditions is colonized in the first days by aerobic enterobacteria, streptococci and staphylococci. When intestinal oxygen level decreases, the gastrointestinal tract is colonized by anaerobic Bifidobacterium sp., Bacteroides sp. and Clostridium sp. e predominance of bifidobacteria is observed in breast-fed infants. Metabolic activities of bifidobacteria that synthesize acetic and lactic acids maintain the balance between intestinal bacteria such as clostridia or enterobacteria and prevent their domination (Harmsen et al., 2000) . Intestinal micro ora in newborns and infants who developed AD is characterized by the increased population of Clostridium sp. and reduced number of Bifidobacterium cells (Kalliomaki et al., 2001; Kirjavainen et al., 2001) . It was presented that supplementation of infant diet with probiotic Lactobacillus strains a ects the composition of intestinal microbiota as well as AD development and severity (Kalliomaki et al., 2001) . Currently hygiene theory has been modified in the direction of the microbita theory (Rocha, 2006; Cukrowska, 2008) . Microbiota theory assumes that the fundamental processes governing the development of resistance and the development of immunological tolerance to external antigens are physiologically microorganisms colonizing the gastrointestinal tract (intestinal microbiota). Delayed and/or altered gastrointestinal colonization during the formation of the intestinal ecosystem can activate the immune system towards promoting allergy. Microbiota theory assumes that the physiological colonization that occurs in healthy infants and activates 1 lymphocytes regulate the immune response, which are responsible for maintaining the 1/ 2 cytokine balance and the development of tolerance to external antigens. Neonatal gastrointestinal tract, which in fetal life remains sterile is settled bacteria from the mother (from faeces, vaginal and skin) or from the external environment (hospital, home, siblings, medical sta ) (Cukrowska, 2008) .
is study aimed at characterization of changes in intestinal microbiota in infants with AD caused by dietary supplementation with Lactobacillus casei DN -114001. Fecal microbiota was analyzed before, just a er finishing bacteria intake, and then a er 5 months from its completion.
Experimental

Materials and Methods
Study design. e trial was carried out in a double-blind, randomized, placebo-controlled way. e samples of probiotic preparation were prepared and blinded in the Institute of Fermentation Technology and Microbiology at the Technical University of Lodz.
ey were de-blinded on completion of the experiment. e study included 40 children aged 6-18 months with recognized AD. e clinical symptoms of AD were measured using SCORAD (Score Atopic Dermatitis) index, and children with medium-severe AD (SCO-RAD < 45.0) were involved in this trial. A group of children (n= 18) whose diet was supplemented with Lactobacillus casei DN -114001 cells (10 9 cells daily) was designated as DN Group (DNG). e diet of the control group of children (n= 22), designated as Placebo Group (PG), was supplemented with a carrier of bacterial cells. ere was no di erences between DNG and PG groups in age, physical development (weight and length), family occurrence of atopic diseases, and the number of children still breast-feeding (19% and 22%, respectively) . e experiment was carried out for 8 months. e children were administered either the probiotic or the placebo for 3 months. During the experiment cow's milk proteins were eliminated from the diet of children or breast-feeding mothers. Fecal microbiota was analyzed before (0), just a er finishing 3 month dietary supplementation (3 m), and than a er 5 months from its completion (8 m). e study was conducted with the permission of the Bioethics Committee of e Children's Memorial Health Institute, and written parental consent.
Probiotic preparation. Bacterial strain Lactobacillus casei DN -114001 was obtained from Danone Ltd. It was cultured in a liquid MRS broth (BTL, Poland) for 48 h at 37°C, in an atmosphere containing 5% (v/v) CO 2. Bacterial cells were pelleted by centrifuging (4000 rpm, 6°C). Cell pellet was washed 3 times with physiological saline solution and centrifuged under the same conditions. en it was suspended in 10% solution of the carrier, i.e. a hydrolyzed milk for children with cow's milk protein allergy -Nutramigen (Mead Johnson, e Netherlands) and lyophilized. e lyophilized bacterial preparation, containing bacterial cells and the carrier, was divided into equal portions (200 mg), each containing 10 9 living cells. Sample collection and preparation. Samples of fresh faeces taken from children (the first stool on that day) in three experimental periods (0, 3 m, 8 m) were immediately placed in anaerobic chamber. All preparation procedures were performed in oxygen-free atmosphere (H:N:CO 2 ; 1:8:1). Samples of approximately 1 g (wet weight) were homogenized in physiological salt solution at the ratio of 1:10 (w/v). en, 1 ml of the feces homogenate was used to prepare a series of 10-fold dilutions (from 10 1 to 10 10 ). Microbial analysis. Children's fecal microbiota was analyzed by the standard plate tests. e following groups of microorganisms were quantified on selective media: Lactobacillus sp., Rogosa Agar (Merck); Bifdobacterium sp., RB Agar (Hartemink et al., 1996) ; Clostridium sp., TSC Agar (Merck); Bacteroides sp., Schaedler Agar (BioMerieux) supplemented with 5% (v/v) sheep blood, kanamycine-vankomycine mixture (BioMerieux) and vitamin K 0.01% (w/v); Enterococcus sp., Bile Aesculin Agar (Merck); Enterobacteriaceae family, Mac Conckey Agar (Merck); and the total number of anaerobic bacteria was determined using Schaedler Agar (BioMerieux). Lactobacillus sp. was cultivated for 48 h at 37°C in CO 2 (5%, v/v) atmosphere (WTC Binder CO 2 Incubator, Germany). e bacteria, Bifidobacterium sp., Clostridium sp., and Bacteroides sp., and total anaerobic bacteria, were cultured at 37°C in the anaerobic atmosphere of H:N:CO 2 (1:8:1) (Anaerobic Workstation Concept 400, Biotrace Int.) for 4 days (Klewicka et al., 2009 ). e results were present as Log 10 CFU/g per gram wet weight of faeces.
Statistical analyses. e results were analyzed using the t-test (One-Way ANOVA test or Welch's test) with P≤ 0.05 considered to be significant.
Results
Faeces of children contained: Lactobacillus sp., Bifidobacterium sp., Bacteroides sp., Clostridium sp., Enterococcus sp. and bacteria of Enterobacteriaceae family.
Before the dietary supplementation, total counts of Lactobacillus, Bifidobacterium, Bacteroides and Enterococcus bacteria in both groups of children were not statistically di erent. In both groups DNG and PG the population of Lactobacillus cells a er 3 months of treatment decreased by 18% and 15% to 6.4 Log 10 CFU/g and 6.54 Log 10 CFU/g, respectively. A decrease in Lactobacillus number was also observed a er next 5 month, but only in control PG group to 5.9 Log 10 CFU/g, whereas in DN group the count of Lactobacillus was maintained at 6.38 Log 10 CFU/g. In DNG group the level of Bifidobacterium cells was stabilized a er 3-month treatment, and only a er the next 5 months it was decreased by 9.4% to 5.57 Log 10 CFU/g. By contrast, in PG group the bifidobacteria were reduced by 9.5% and 24% a er 3 and 5 months, respectively. During 3-month dietary supplementation the number of Clostridium cells was decreased by 10% in DNG group level was maintained during the next 5 months. In PG group the number of Clostridium sp. was kept at almost the same level during the whole study. None statistical di erences were found in counts of Bacteroides sp., Enterobaceriaceae, and Enterococcus sp. throughout the experiment (Table I) .
In both DNG and PG groups clinical improvement, i.e. a decrease in SCORAD index was observed, but a significant decrease a er 8 months as compared with 3-month lasting observation was found only in DNG group (Table II) . In all children treated with probiotics a decrease in SCORAD was found. In contrast to DNG group, in three children treated with placebo clinical condition deteriorated.
eir SCORAD index a er 8 months was higher than before treatment. 
Discussion
Our experiment showed that the dietary supplementation of children su ering from AD with the probiotic bacteria Lactobacillus casei DN 114001 modulated the profile of intestinal microbiota in terms of the counts of Bifidobacterium, Clostridium and Lactobacillus sp. Rinne et al. (2005) supplemented the diet of infants with genetic predisposition to allergic disorders (the occurrence of atopy in the family) with bacteria Lactobacillus rhamnosus GG for 4 weeks and monitored changes in their fecal microbiota considering cells of Bifidobacterium and Lactobacillus/Enterococcus (by FISH method).
ey found the successive decrease in the number of Bifidobacterium cells in the period between the 3 rd and 12 th month both in the probiotic and control (placebo) groups. By contrast, in our study the population of intestinal Bifidobacterium sp. in the children administered with bacteria Lactobacillus casei DN -114001 was stabilized during the treatment and was decreased only a er the next 5 months. Bifidobacterium sp. rank among the most important, healthpromoting microorganisms that colonize the human gastrointestinal tract. Molecular study of Favier et al., (2002) revealed that in breast-fed newborns bifidobacteria account for 60-90% total fecal microbiota. ey are thought to modulate the activity of the immune system. An inhibitor of serine protease, which is identical with its eukaryotic homologue exerting the immunomodulating activity, was identified in the genome of Bifidobacterium longum (Schell et al., 2002) . Bifidobacterium sp. are capable of adapting to conditions inside the gastrointestinal tract of newborns and their metabolic activities foster maturation and formation of the appropriate intestinal biocenose. e number of intestinal Bifidobacterium cells decreases with age when children are fed regular diet. erefore, the maintenance of relatively high counts of Bifidobacterium sp. is of particular importance in individuals with dysfunction of intestinal micro ora. Our study showed that dietary supplementation with Lactobacillus casei DN -114001 fosters the predominance of bifidobacteria.
e other positive e ect of treatment with Lactobacillus casei DN -114001 was reduction in Clostridium sp. counts. Because of potential patogenicity and synthesis of toxins the abundance of clostridia is undesired (Salminen et al., 1998) . In healthy infants, the predominant fecal bacteria are Bifidobacterium sp. and Lactobacillus sp. By contrast, in infants who developed allergic disorders the population of Bifidobacterium is reduced while the population of Clostridium sp. is increased (Kalliomaki et al., 2001; Ouwehand et al., 2002) . Analysis of e ects of probiotics on the composition and counts of intestinal microbiota that were reported by various groups of researchers shows that treatment with di erent probiotic bacteria strains causes di erent levels of modulation. For instance, Garrido et al. (2005) supplemented the diet of healthy individuals with Lactobacillus johnsonii La1 and observed that population of Bifidobacterium was increased by 5% while counts of Clostridium sp., Bacteroides sp. and Enterococcus sp. were not a ected. Another trial, consisting in treatment of infants with family predisposition to atopic dermatitis and bronchial asthma with probiotic Bifidobacterium lactis BB12 revealed that the count of Clostridium sp. was reduced only in breast-fed children who were not fed the probiotic. In the children who were fed Bifidibacterium lactis BB12 the clostridium bacteria were in the same level (Rinne et al., 2005) . Adlerberth et al., (2007) found that the risk of AD development increased with the level of intestinal Clostridium sp. in infancy. Our study presented that an attractive property of Lactobacillus casei DN -114001 is its capability of reducing the count of Clostridium sp. in children with AD. Importance of those strains in treatment of AD still are inconclusive. Our observation showed that they could play role in long-lasting clinical improvement.
Results of this study and available reports demonstrate that the modulation of intestinal ecosystem in children with atopic dermatitis, consisting in reducing or increasing counts of various groups of microorganisms by di erent probiotic bacteria is strain-dependent. Supplementation of AD children diet with the strain Lactobacillus casei DN -114001 positively a ects population of Bifidobacterium sp. and reduces counts of Clostridium sp. and additionally stabilize Lactobacillus population. 
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